BioSpace News Archive

In the ongoing effort to combat Human Coronavirus, SiShield’s patented disinfectant and microbiostatic agent combination offers a powerful solution to clean, deodorize, disinfect and protect in one step.

Evofem Biosciences, Inc., announced that two new data sets from its Phase 3 AMPOWER trial evaluating Phexxi® will be presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

Pixee Medical Receives FDA Clearance for Knee + Digitally augmented surgeons are to become a reality in the USA Focus on total knee arthroplasty in ambulatory surgery centers

GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the appointment of Amin Khan as the company’s Chief Scientific Officer, Human Health.

Smiths Medical, a leading medical device manufacturer, announces the launch of the acapella® choice blue vibratory PEP therapy system.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

The results of a large, national heart attack study show that patients with a deadly complication known as cardiogenic shock survived at a significantly higher rate when treated with a protocol developed by cardiologists at Henry Ford Hospital in collaboration with four metro Detroit hospitals.

NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI

The CIBMTR® (Center for International Blood & Marrow Transplant Research®) manuscript, entitled “A National Marrow Donor Program Sponsored Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide,” has been published in the Journal of Clinical Oncology

Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.